Products for Research Use Only
RegisterLogin

BGC0222

CAT: 0804-HY-P10783Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P10783Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BGC0222 is a novel prodrug of Irinotecan. BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors[1].
UNSPSC
12352209
Target
Integrin; Peptide-Drug Conjugates (PDCs)
Related Pathways
Antibody-drug Conjugate/ADC Related; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C(NCCCC[C@@H](C(NCC(O[C@@]1(C(OCC2=C1C=C3C4=NC5=CC=C(C=C5C(CC)=C4CN3C2=O)OC(N6CCC(CC6)N7CCCCC7)=O)=O)CC)=O)=O)NC(COCCOCCOCCOCCOCCOCCNC(CC[C@@H]8NC([C@H](NC([C@@H](NC(CNC([C@@H](NC8=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)COCCOCC(COCCOCC(NCCCC[C@@H](C(NCC(O[C@@]%10(C(OCC%11=C%10C=C%12C%13=NC%14=CC=C(C=C%14C(CC)=C%13CN%12C%11=O)OC(N%15CCC(CC%15)N%16CCCCC%16)=O)=O)CC)=O)=O)NC(COCCOCCOCCOCCOCCOCCNC(CC[C@@H]%17NC([C@H](NC([C@@H](NC(CNC([C@@H](NC%17=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC%18=CC=CC=C%18)=O)=O)=O)=O)(COCCOCC(NCCCC[C@@H](C(NCC(O[C@@]%19(C(OCC%20=C%19C=C%21C%22=NC%23=CC=C(C=C%23C(CC)=C%22CN%21C%20=O)OC(N%24CCC(CC%24)N%25CCCCC%25)=O)=O)CC)=O)=O)NC(COCCOCCOCCOCCOCCOCCNC(CC[C@@H]%26NC([C@H](NC([C@@H](NC(CNC([C@@H](NC%26=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC%27=CC=CC=C%27)=O)=O)=O)=O)COCCOCC(NCCCC[C@@H](C(NCC(O[C@@]%28(C(OCC%29=C%28C=C%30C%31=NC%32=CC=C(C=C%32C(CC)=C%31CN%30C%29=O)OC(N%33CCC(CC%33)N%34CCCCC%34)=O)=O)CC)=O)=O)NC(COCCOCCOCCOCCOCCOCCNC(CC[C@@H]%35NC([C@H](NC([C@@H](NC(CNC([C@@H](NC%35=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC%36=CC=CC=C%36)=O)=O)=O)=O
Molecular Formula
C1241H2276N64O552
Molecular Weight
26927.36
References & Citations
[1]Huang YQ, et al. Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent. Eur J Med Chem. 2018 Oct 5, 158:82-90.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported

Alternative Products

CatalogName
T203374-01BGC0222

Popular Products